Dr. Nallathamby presented on his abiotic biomimicking antibacterial Nanoparticles, and how they were successfully tested against A. baumannii BA1605 S.aureus USA300, P.aeruginosa FRD1, K. pneumoniae, C.striatum, E. faecalis, and S. pyogenes. We saw little to no evolution of resistance at doses above the MIC. Additionally, we observed what looks like inflammation-free wound healing in mouse and rat models. The wound size stabilizes as soon as the formulation is …
Category Archive: MHSRS
Recent Posts
- Military Health Sciences Research Symposium 2024. (Aug 26-29, 2024, Kissimmee FL) August 30, 2024
- Sustained and Controlled Antibiotics Release for Prolonged Antibacterial Action Against MRSA, and Pseudomonas aeruginosa August 21, 2024
- Precision Health and Diagnostics Session Chair at Techconnect World Innovation Conference (2024) June 19, 2024
- MTEC Annual meeting in Baltimore MD (May 24, 2024) May 24, 2024
- Nallathamby Lab’s Kevin Armknecht is Invited to Present at the Midwest Microscopy and Microanalysis Workshop 2024 May 7, 2024
Archives
Categories
NIH Funding Opportunities
- Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional) December 6, 2024Funding Opportunity PAR-24-330 from the NIH Guide for Grants and Contracts. This PAR is being reissued in accordance with the simplified review criteria in effect for application due dates after January 25, 2025. The objective of this funding opportunity is to support non-pharmacological interventions to promote sleep health, reduce sleep health disparities, and examine sleep […]
- Notice to Extend K01 Notice of Funding Opportunity December 6, 2024Notice NOT-OH-25-003 from the NIH Guide for Grants and Contracts
- Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) December 6, 2024Funding Opportunity RFA-TR-25-002 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents […]
- Notice of Expiration of PA-21-235, NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed) December 6, 2024Notice NOT-MH-25-085 from the NIH Guide for Grants and Contracts
- Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed) December 6, 2024Funding Opportunity RFA-HG-25-007 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) will renew the Human Genome Reference Program (HGRP). This Informatics Tools for the Pangenome NOFO will provide multiple awards to develop informatics tools that enable uptake and use of the improved pangenome reference. Emphasis will be on […]
- Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) December 6, 2024Funding Opportunity PAR-25-298 from the NIH Guide for Grants and Contracts. The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have […]
- NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 Independent Clinical Trial Not Allowed) December 6, 2024Funding Opportunity PAR-24-286 from the NIH Guide for Grants and Contracts. The primary goal of the NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22) Program (hereafter abbreviated as the NIMH Career Transition K22 Program) is to provide support for career intramural investigators at NIMH who aim to transition from the Division of Intramural Research […]
- Notice of Virtual Question and Answer Office Hours for Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program Applicants December 6, 2024Notice NOT-GM-25-014 from the NIH Guide for Grants and Contracts
- Notice of Intent to Publish a Funding Opportunity Announcement for Academic Career Excellence (ACE) Award (K32 Independent Clinical Trial Not Allowed) December 6, 2024Notice NOT-CA-25-016 from the NIH Guide for Grants and Contracts
- Notice of Intent to Publish a Funding Opportunity Announcement for Academic Career Excellence (ACE) Award (K32 - Independent Clinical Trial Required) December 6, 2024Notice NOT-CA-25-017 from the NIH Guide for Grants and Contracts
Recent Comments